Back to User profile » Dr Jia-Yi Wu
Papers published by Dr Jia-Yi Wu:
Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?
Wu JY, Wu JY, Liu DY, Li H, Zhuang SW, Li B, Zhou JY, Huang JY, Zhang ZB, Li SQ, Yan ML, Wang YD
Journal of Hepatocellular Carcinoma 2023, 10:2161-2171
Published Date: 5 December 2023
Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy
Luo MC, Wu JY, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, Yan ML
Journal of Hepatocellular Carcinoma 2023, 10:1827-1837
Published Date: 12 October 2023
Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
Li SQ, Wu JY, Wu JY, Xie H, Li JH, Zeng ZX, Fu YK, Liu DY, Li H, Chen WZ, Huang JY, Yan ML
Journal of Hepatocellular Carcinoma 2023, 10:1799-1811
Published Date: 11 October 2023
Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML
Journal of Hepatocellular Carcinoma 2021, 8:1233-1240
Published Date: 5 October 2021
A Prognostic Scoring System for Predicting Overall Survival of Patients with the TNM 8th Edition Stage I and II Hepatocellular Carcinoma After Surgery: A Population-Based Study
Bai Y, Lian Y, Wu J, Chen S, Lai J, Zheng Y, Tian Y, Yan M, Wang Y
Cancer Management and Research 2021, 13:2131-2142
Published Date: 2 March 2021